KEYMAKER-U02
Enrolling By Invitation
18 years - 99 years
All
Phase
1
15 participants needed
1 Location
Brief description of study
Patients will be recruited from within the Penn Medicine Abramson Cancer Center pool of patients.
This sub-study is part of a larger research study that is testing experimental treatments for melanoma. This sub-study is testing experimental drugs when they are given before and/or after melanoma surgery. Subjects will be assigned to one of 2 groups. Group 1: pembrolizumab and MK-7684 before surgery, and pembrolizumab after surgery. Group 2: pembrolizumab and V937 before surgery, and pembrolizumab after surgery.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Melanoma
-
Age: 18 years - 99 years
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 848899
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
